DEXYCU KIT (dexamethasone) by Merck & Co. is corticosteroid hormone receptor agonists [moa]. Approved for multiple myeloma, anterior uveitis. First approved in 2018.
Drug data last refreshed 20h ago · AI intelligence enriched 1w ago
DEXYCU KIT is a corticosteroid suspension containing dexamethasone administered via intraocular injection for treatment of Multiple Myeloma and Anterior Uveitis. It works by agonizing corticosteroid hormone receptors to reduce inflammation and suppress immune-mediated tumor growth. The intraocular route enables localized delivery to the eye with systemic corticosteroid effects.
Product is in peak commercial phase with extended patent protection through 2039; stable team size expected with focus on market penetration and indication expansion.
Corticosteroid Hormone Receptor Agonists
Corticosteroid
HEM-iSMART E: Capivasertib + Venetoclax + Dexamethasone in Pediatric Patients With Relapsed or Refractory Hematological Malignancies
Study of Selinexor With Carfilzomib, Isatuximab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma
A Non-interventional Study of Melphalan Flufenamide (Melflufen) (Pepaxti®) and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma (R/RMM)
Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
Belantamab Mafodotin or Daratumumab With Bortezomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma
Worked on DEXYCU KIT at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moDEXYCU KIT offers career opportunities in a specialty oncology/ophthalmology product with stable peak-stage commercial trajectory and long patent protection through 2039. Roles span commercial execution (brand, sales, market access) and medical affairs, with emphasis on defending market share against diverse competitor mechanisms and managing off-label utilization.